SG11202108679PA - Type i interferon-mediated disorders - Google Patents

Type i interferon-mediated disorders

Info

Publication number
SG11202108679PA
SG11202108679PA SG11202108679PA SG11202108679PA SG11202108679PA SG 11202108679P A SG11202108679P A SG 11202108679PA SG 11202108679P A SG11202108679P A SG 11202108679PA SG 11202108679P A SG11202108679P A SG 11202108679PA SG 11202108679P A SG11202108679P A SG 11202108679PA
Authority
SG
Singapore
Prior art keywords
interferon
type
mediated disorders
mediated
disorders
Prior art date
Application number
SG11202108679PA
Inventor
Kerry Casey
Dominic Sinibaldi
Michael Smith
Miguel Sanjuan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11202108679PA publication Critical patent/SG11202108679PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • G01N2333/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202108679PA 2019-02-15 2020-02-14 Type i interferon-mediated disorders SG11202108679PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806002P 2019-02-15 2019-02-15
PCT/EP2020/053962 WO2020165437A1 (en) 2019-02-15 2020-02-14 Type i interferon-mediated disorders

Publications (1)

Publication Number Publication Date
SG11202108679PA true SG11202108679PA (en) 2021-09-29

Family

ID=69591655

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108679PA SG11202108679PA (en) 2019-02-15 2020-02-14 Type i interferon-mediated disorders

Country Status (13)

Country Link
US (1) US20220162325A1 (en)
EP (1) EP3924383A1 (en)
JP (1) JP7522749B2 (en)
KR (1) KR20210131354A (en)
CN (1) CN113508138B (en)
AU (1) AU2020222262B2 (en)
BR (1) BR112021015596A2 (en)
CA (1) CA3128785A1 (en)
EA (1) EA202192176A1 (en)
IL (1) IL285321A (en)
MA (1) MA54937A (en)
SG (1) SG11202108679PA (en)
WO (1) WO2020165437A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020382850A1 (en) * 2019-11-11 2022-06-23 Astrazeneca Ab Type I interferon inhibition in systemic lupus erythematosus
EP4306541A3 (en) 2021-04-23 2024-03-27 Astrazeneca AB Anti-ifnar1 dosing regime for subcutaneous injection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US941004A (en) 1906-03-24 1909-11-23 Brandt Cashier Company Calculating implement.
WO1984003106A1 (en) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (en) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim NEW IMMUNGLOBULIN-PRODUCING HYBRID CELL LINES, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF
DE3685996T2 (en) 1985-06-11 1993-01-14 Ciba Geigy Ag HYBRID INTERFERONE.
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2523142A1 (en) 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
RU2600884C2 (en) 2004-06-21 2016-10-27 Е. Р. Сквибб энд Сонз, Эл,Эл.Си Interferon alpha 1 receptor antibodies and use thereof
JP2010512315A (en) 2006-12-06 2010-04-22 メディミューン,エルエルシー Interferon alpha-inducible pharmacodynamic marker
KR101666229B1 (en) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Anti-ifnar1 antibodies with reduced fc ligand affinity
CN102753704A (en) * 2009-09-03 2012-10-24 米迪缪尼有限公司 Type 1 interferon diagnostic
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists

Also Published As

Publication number Publication date
IL285321A (en) 2021-09-30
JP2022520417A (en) 2022-03-30
US20220162325A1 (en) 2022-05-26
AU2020222262B2 (en) 2024-06-20
JP7522749B2 (en) 2024-07-25
EA202192176A1 (en) 2022-01-13
BR112021015596A2 (en) 2021-10-05
WO2020165437A1 (en) 2020-08-20
EP3924383A1 (en) 2021-12-22
CA3128785A1 (en) 2020-08-20
MA54937A (en) 2021-12-22
CN113508138A (en) 2021-10-15
AU2020222262A1 (en) 2021-09-30
KR20210131354A (en) 2021-11-02
CN113508138B (en) 2024-08-09

Similar Documents

Publication Publication Date Title
GB201910452D0 (en) Electrode
EP3773572A4 (en) Rimegepant for cgrp related disorders
CA189498S (en) Showerbase
GB201800761D0 (en) Interaction between blockchains
GB201910188D0 (en) Analyser
IL286258B (en) Carrying assembly
IL285321A (en) Type i interferon-mediated disorders
GB201912429D0 (en) Barries
GB201900665D0 (en) 06557607002
GB201803010D0 (en) Neurodegenerative disorders
CA189673S (en) Uroflowmeter
CA190384S (en) Beverageware
CA189047S (en) Hammock-tent
GB201905857D0 (en) Aerostructure assembly
DK3947966T3 (en) Fremgangsmåde til at detektere et læk i et hydraulisk pitchsystem
GB2588486B (en) Former
CA189434S (en) Jerrycan
GB2586151B (en) Mono-structure
CA187366S (en) Hoodie
CA187077S (en) Velomobile
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
GB202013791D0 (en) Tidysqueeze 9
GB201917053D0 (en) Bioselection approach
GB201917052D0 (en) Bioselection approach